scholarly journals Epizootiological investigation of equine herpesvirus type 1 infection among Japanese racehorses before and after the replacement of an inactivated vaccine with a modified live vaccine

2019 ◽  
Vol 15 (1) ◽  
Author(s):  
Hiroshi Bannai ◽  
Koji Tsujimura ◽  
Manabu Nemoto ◽  
Minoru Ohta ◽  
Takashi Yamanaka ◽  
...  
2014 ◽  
Vol 21 (8) ◽  
pp. 1070-1076 ◽  
Author(s):  
Hiroshi Bannai ◽  
Naomi Mae ◽  
Hirotaka Ode ◽  
Manabu Nemoto ◽  
Koji Tsujimura ◽  
...  

ABSTRACTEquine herpesvirus type 1 (EHV-1) is a major cause of winter pyrexia in racehorses in two training centers (Ritto and Miho) in Japan. Until the epizootic period of 2008-2009, a vaccination program using a killed EHV-1 vaccine targeted only susceptible 3-year-old horses with low antibody levels to EHV-1 antigens. However, because the protective effect was not satisfactory, in 2009-2010 the vaccination program was altered to target all 3-year-old horses. To evaluate the vaccine's efficacy, we investigated the number of horses with pyrexia due to EHV-1 or equine herpesvirus type 4 (EHV-4) infection or both and examined the vaccination coverage in the 3-year-old population and in the whole population before and after changes in the program. The mean (± standard deviation [SD]) estimated numbers of horses infected with EHV-1 or EHV-4 or both, among pyretic horses from 1999-2000 to 2008-2009 were 105 ± 47 at Ritto and 66 ± 44 at Miho. Although the estimated number of infected horses did not change greatly in the first period of the current program, it decreased from the second period, with means (±SD) of 21 ± 12 at Ritto and 14 ± 15 at Miho from 2010-2011 to 2012-2013. Vaccination coverage in the 3-year-old population was 99.4% at Ritto and 99.8% at Miho in the first period, and similar values were maintained thereafter. Coverage in the whole population increased more gradually than that in the 3-year-old population. The results suggest that EHV-1 epizootics can be suppressed by maintaining high vaccination coverage, not only in the 3-year-old population but also in the whole population.


Vaccine ◽  
2008 ◽  
Vol 26 (19) ◽  
pp. 2335-2343 ◽  
Author(s):  
Cristina Rosas ◽  
Gerlinde R. Van de Walle ◽  
Stephan M. Metzger ◽  
Karin Hoelzer ◽  
Edward J. Dubovi ◽  
...  

2017 ◽  
Vol 51 ◽  
pp. 46-53
Author(s):  
Maksat Akhmedzhanov ◽  
Rysbek Nurgaziev ◽  
Jailobek Orozov ◽  
Irmgard Moser ◽  
Nikolaus Osterrieder ◽  
...  

Author(s):  
Alok Joshi ◽  
R.P. Gupta ◽  
Selvaraj Pavulraj ◽  
Bidhan Chandra Bera ◽  
Taruna Anand ◽  
...  

Background: Equine herpesvirus type 1 (EHV-1) is the most important viral pathogen of equines, causing respiratory illness, abortion, neonatal foal mortality and neurologic disorders. Large numbers of commercial EHV-1 vaccines are available to protect equines from the disease, but they provide only partial protection. Despite immunization with inactivated and modified live virus vaccine, mares show abortions. Present study was aimed to investigate the immunogenicity and protective efficacy of EHV-1 recombinant glycoprotein B (rgB) and gB expressing plasmid DNA against EHV-1 infection in BALB/c mice model.Methods: About 3-4 weeks old 225 female BALB/c mice were selected for the comparative study of immunization followed by challenged with EHV-1/India/Tohana/96-2 strain virus in 5 different groups of 45 animals each.Result: Following immunization, rgB vaccinated mice showed optimal stimulation of EHV-1 gB specific cell mediated and humoral mediated immunity (HMI and CMI). The gB expressing plasmid DNA vaccinated mice developed only CMI while inactivated whole virus vaccinated mice had only HMI. Upon EHV-1 challenge, all infected mice displayed variable levels of clinical signs with changes in body weight, however, vaccinated mice showed very rapid recovery with optimal protection. Positive control group mice showed severe pulmonary lesions along with persistence virus infection till 5 days post challenge (dpc) whereas vaccinated mice had less pulmonary lesion only up to 3dpc. Minimal lung lesions and early virus clearance was observed in the rgB immunized mice in comparison to the gB plasmid DNA and inactivated EHV-1 vaccine immunized mice. It has been concluded that immunization with rgB elicits optimum protective immune response against EHV-1 infection in mice model. The rgB could be a potential vaccine candidate against EHV-1 infection in equine in the future.


2015 ◽  
Vol 179 (3-4) ◽  
pp. 304-309 ◽  
Author(s):  
Gaby van Galen ◽  
Agnes Leblond ◽  
Pierre Tritz ◽  
Ludovic Martinelle ◽  
Stéphane Pronost ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document